HELP (Helus Pharma) Total Liabilities: $19.38 Mil (As of Mar. 2026)


HELP Helus Pharma Inc HELP
22 GF Score
Price $6.24
! 2 Warning Signs
View Full Analysis

What is Helus Pharma Total Liabilities?

Helus Pharma HELP -0.48% 22 Total Liabilities is $19.38 Mil as of Mar. 2026. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Helus Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was $19.38 Mil.

Helus Pharma's quarterly Total Liabilities declined from Sep. 2025 ($42.25 Mil) to Dec. 2025 ($16.18 Mil) but then increased from Dec. 2025 ($16.18 Mil) to Mar. 2026 ($19.38 Mil).

Helus Pharma's annual Total Liabilities increased from Mar. 2024 ($7.47 Mil) to Mar. 2025 ($14.90 Mil) and increased from Mar. 2025 ($14.90 Mil) to Mar. 2026 ($19.38 Mil).

Helus Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Helus Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Total Liabilities Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial 6.33 4.19 7.47 14.90 19.38

Helus Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.90 59.05 42.25 16.18 19.38
HELP
22GF Score
Helus Pharma Inc HELP
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Helus Pharma's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.377+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=19.38

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=251.166-231.789
=19.38

Helus Pharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.377+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=19.38

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=251.166-231.789
=19.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $19.38 Mil mean?
Helus Pharma (HELP) has a Total Liabilities of $19.38 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Helus Pharma and its competitors.
Is Helus Pharma's Total Liabilities too high?
Helus Pharma's current Total Liabilities is $19.38 Mil. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Total Liabilities compare to VRTX and REGN?
Helus Pharma's Total Liabilities of $19.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Helus Pharma and its competitors. Helus Pharma's current Total Liabilities is $19.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current Total Liabilities of $19.38 Mil. The current Total Liabilities is $19.38 Mil. Helus Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Helus Pharma (HELP), the current Total Liabilities is $19.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score

Get the complete analysis for HELP

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.24
Price